Quick Answer
IGC Pharma, Inc. reported Cash and Equivalents of $405.0 thousand for fiscal year 2025.
IGC Pharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $405.0K | -66.2% |
| 2024 | $1.20M | -62.5% |
| 2023 | $3.20M | -69.4% |
| 2022 | $10.46M | -28.1% |
| 2021 | $14.55M | +100.4% |
| 2020 | $7.26M | -71.7% |
| 2019 | $25.61M | +1444.6% |
| 2018 | $1.66M | +208.2% |
| 2017 | $538.0K | -63.9% |
| 2016 | $1.49M | +80.8% |
| 2015 | $824.5K | -19.7% |
| 2014 | $1.03M | -3.6% |
| 2013 | $1.06M | +89.1% |
| 2012 | $562.9K | -64.4% |
| 2011 | $1.58M | +87.8% |
| 2010 | $842.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.10M | -28.5% | +143.4% |
| June 30, 2025 | $454.0K | -75.1% | +12.1% |
| March 31, 2025 | $405.0K | -66.2% | -13.8% |
| December 31, 2024 | $470.0K | -65.9% | -69.6% |
| September 30, 2024 | $1.55M | -48.9% | -15.2% |
| June 30, 2024 | $1.82M | +5.9% | +52.3% |
| March 31, 2024 | $1.20M | -62.5% | -13.1% |
| December 31, 2023 | $1.38M | -72.1% | -54.5% |
- IGC Pharma, Inc. showed a decrease of -66.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, IGC Pharma, Inc.’s cash and equivalents has declined by 52.0% (from $842.9 thousand to $405.0 thousand).
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: